“Adding great talent to our Board builds a strong foundation for the momentum of PanTheryx”

“As we continue to advance our colostrum-based offerings and educate consumers about the wide array of colostrum benefits, bringing talented individuals who can help us achieve this mission is essential,” said David Abramson, executive chairman of PanTheryx. “Both Holger and Peter come with compelling industry backgrounds and track records of unparalleled commercial success and scientific advancement in nutrition and food science, and we could not be happier that they have agreed to join our Board.”

Mr. Liepmann has been consistently recognized for his leadership skills and business results throughout a more than 35-year career in the health care environment, including experience in pharmaceutical, nutritional and hospital products and roles in R&D, manufacturing, supply chain and commercial operations. Liepmann had an extensive and successful career with Abbott Laboratories, most recently serving as executive vice president for Abbott’s $5.0+ billion Global Nutrition business. Prior to Abbott, Liepmann worked for Bayer AG in a variety of capacities, in both the US and Germany. He has been advising boards since 2002, continuing to serve on the board of Altan Pharmaceuticals and the board of trustees of the DRI Foundation. He earned his Bachelor's degree from Dartmouth College and a Master’s degree in business administration from Stanford University.

Mr. Erickson brings more than 30 years of food science expertise to the PanTheryx Board, most recently serving as executive vice president for innovation, technology and quality at General Mills Inc. He is credited with building a culture focused on industry-leading innovation, technical excellence, product quality, and food safety; resulting in the invention and commercialization of advanced food and technologies that benefit the lives of consumers globally. Erickson has remained committed to driving innovation and delivering safer, more effective products to consumers through his active board service with Noblegen Inc. and Wenger Corporation. Erickson received a Bachelor of Science and Master of Science in food science from University of Massachusetts.

“Adding great talent to our Board builds a strong foundation for the momentum of PanTheryx,” said Wes Parris, president, CEO and director of PanTheryx. “We are poised to provide an exciting portfolio of colostrum-based solutions for a wide range of health benefits for consumers and are thrilled to have these two exceptional leaders join an impressive group of individuals on our Board. Their combination of business knowledge, global leadership and industry contacts will be instrumental in meeting our goals.”

Liepmann and Erickson join the existing Board members, including David Abramson, executive chairman of PanTheryx; Craig Cogut, founder and co-managing partner of Pegasus Capital Advisors; David Cogut, principal at Pegasus Capital Advisors; Dr. Mehmet Oz, M.D, surgeon and host of The Dr. Oz Show; Wes Parris, president, CEO and director of PanTheryx; Dr. Rajiv Shah, M.D., president of the Rockefeller Foundation and Tom Washing, founding partner of Sequel Venture Partners.

About PanTheryx:

PanTheryx is a biotechnology company committed to realizing the potential of bovine colostrum to address a wide range of health conditions. As the world’s largest producer of bovine colostrum, PanTheryx utilizes the cellular and biomolecular processes of bovine colostrum to produce a wide range of therapeutics, spanning the range of nutritional interventions to biologics. PanTheryx’s proprietary colostrum, ColostrumOne™ is nature’s superfood; designed to be comprehensive as nature intended with the important nutritional components for health and vitality throughout all stages of life. Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA. For more information, please visit PanTheryx.com